Inovio Pharmaceuticals spinoff Geneos Therapeutics will put the proceeds from the series A1 round towards advancing its liver cancer vaccine candidate.
US-based immuno-oncology therapy developer Geneos Therapeutics closed its series A1 round at $12m yesterday, raising the cash from a consortium including biotechnology company Inovio Pharmaceuticals.
The round was led by venture capital firm Korea Investment Partners’ Global Bio Fund with participation from all the company’s series A investors. It had raised $10.5m from Inovio and VC firm Santé Ventures in early 2019.
Geneos was spun off by Inovio to develop personalised therapies treatments for cancer based on each patient’s…
